PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

It was inevitable. When a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech arguments had to multiply. And they have, in cases across the country, testing that Second Circuit decision in other regions. Report